To amend title XIX of the Social Security Act to require the Secretary of Health and Human Services to issue guidance to States on which tests for the screening and early detection of preeclampsia may be covered under the Medicaid program and the Children's Health Insurance Program.
Summary
HR9061 is a procedural early-stage bill requiring HHS to issue guidance on preeclampsia screening coverage under Medicaid/CHIP. No funding or mandate is provided, and the bill remains in committee with low legislative momentum. No direct market impact is anticipated at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill is in early procedural stage with low momentum.
- 2.No funding or mandate; only requires HHS to issue guidance.
- 3.No identifiable beneficiaries or losers at this time.
Market Implications
No material market impact is expected from HR9061. The bill is purely procedural and has minimal legislative support. Healthcare investors should focus on other catalysts such as CMS reimbursement updates or FDA approvals for preeclampsia tests. Diagnostic stocks are not affected.
Full Analysis
HR9061 was introduced on May 29, 2026, by Rep. Kean (R-NJ) and referred to the House Energy and Commerce Committee. The bill directs the Secretary of HHS to issue guidance to states on which preeclampsia screening tests may be covered under Medicaid and CHIP. It does not appropriate any funds, mandate coverage, or specify particular tests. This is a purely procedural step — the guidance process itself could take months or years, and any actual coverage expansion would require separate state action or further federal rulemaking. The bill has only three cosponsors and no companion legislation in the Senate, indicating limited bipartisan momentum. At this early stage, the probability of enactment is low, and even if passed, the market impact would depend on subsequent state-level adoption and reimbursement rates. No direct revenue streams are affected, and diagnostic testing companies like Quest Diagnostics (DGX), LabCorp (LH), or Hologic (HOLX) face no near-term changes. Investors should monitor committee markup and bipartisan support for signs of progress, but currently there is no actionable signal.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →